Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer

Kawahara, Takashi; Yokomizo, Yumiko; Ito, Yusuke; Ito, Hiroki; Ishiguro, Hitoshi; Teranishi, Jun Ichi; Makiyama, Kazuhide; Miyoshi, Yasuhide; Miyamoto, Hiroshi; Yao, Masahiro; Uemura, Hiroji

doi:10.1186/s12885-016-2134-3

Cited by 40 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The neutrophil‐to‐lymphocyte ratio (NLR) was introduced more recently to represent probably, at least in most cases, the same phenomenon, and this appears to be an even better predictor for poor disease and treatment outcome (reviewed in ). Different types of cancer where a high NLR correlates with poor survival, and in some cases also a worse response to treatment, include melanoma , hepatocellular carcinoma , non–small cell lung cancer , colorectal cancer , nasopharyngeal carcinoma , breast cancer , intrahepatic cholangiocarcinoma , prostate cancer , pancreatic cancer , and gastric cancer . The NLR appears in most cases a reflection of the systemic inflammatory response that occurs as a consequence of the cancer in patients, and it makes sense that this response is most pronounced in advanced cancer .…”

Section: Neutrophils In Cancermentioning

confidence: 99%

Neutrophils in cancer

Treffers

Hiemstra

Kuijpers

et al. 2016

Immunological Reviews

168

145

View full text Add to dashboard Cite

Summary Neutrophils play an important role in cancer. This does not only relate to the well‐established prognostic value of the presence of neutrophils, either in the blood or in tumor tissue, in the context of cancer progression or for the monitoring of therapy, but also to their active role in the progression of cancer. In the current review, we describe what is known in general about the role of neutrophils in cancer. What is emerging is a complex, rather heterogeneous picture with both pro‐ and anti‐tumorigenic roles, which apparently differs with cancer type and disease stage. Furthermore, we will discuss the well‐known role of neutrophils as myeloid‐derived suppressor cells (MDSC), and also on the role of neutrophils as important effector cells during antibody therapy in cancer. It is clear that neutrophils contribute substantially to cancer progression in multiple ways, and this includes both direct effects on the cancer cells and indirect effect on the tumor microenvironment. While in many cases neutrophils have been shown to promote tumor progression, for instance by acting as MDSC, there are also protective effects, particularly when antibody immunotherapy is performed. A better understanding of the role of neutrophils is likely to provide opportunities for immunomodulation and for improving the treatment of cancer patients.

show abstract

Section: Neutrophils In Cancermentioning

confidence: 99%

Neutrophils in cancer

Treffers

Hiemstra

Kuijpers

et al. 2016

Immunological Reviews

168

145

View full text Add to dashboard Cite

show abstract

“…The neutrophil-to-lymphocyte ratio (NLR) is one factor that has been widely reported to be a prognostic factor not only in prostate cancer but also in some solid cancers (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). In addition, the NLR can be calculated easily from routine complete blood counts (CBCs) in peripheral blood samples (4,5).…”

Section: Introductionmentioning

confidence: 99%

Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

et al. 2018

Self Cite

View full text Add to dashboard Cite

Abstract. Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil-to-lymphocyte ratio (NLR) has also been investigated for a CRPC treatments in a few reports, however it has not been identified to be a prognostic factor for AA treatment in Japanese patients. The present study aimed to assess the association of the baseline NLR with the overall survival (OS) in CPRC patients treated by AA. The present study retrospectively reviewed a total of 90 consecutive patients with CRPC treated with AA from 2011 to 2016 at

show abstract

“…Metastatic sites are one of the factors that significantly increase the NLR [12, 13]; however, NLR is reportedly useful in distinguishing between PCa patients with no metastatic sites and cancer-free individual through prostate biopsy [9]. In our study, only a single patient had metastasis, and we considered that NLR could be a useful marker based on the past report.…”

Section: Discussionmentioning

confidence: 85%

The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis

Hashimoto¹,

Matsumura²,

Ohzeki³

et al. 2018

Urol Int

View full text Add to dashboard Cite

Introduction: We investigated whether the change in the neutrophil lymphocyte ratio (NLR) from the first to the last repeat prostate biopsy (ΔNLR) could be the diagnostic tool or not for prostate cancer (PCa) detection. Materials and Methods: We retrospectively evaluated medical records of men who had undergone repeat prostate biopsy. The investigated parameters were white blood cell, neutrophil, lymphocyte counts, NLR at the last prostate biopsy, ΔNLR, prostate-specific antigen (PSA), PSA density (PSAD), and PSA velocity. Exclusion criteria were the presence of cancers other than prostate origin, medication, and diseases which induce the change of NLR. Results: A total of 301 men who had undergone repeat prostate biopsy were selected for this study. After applying exclusion criteria, 223 patients were included. Of these patients, 94 were diagnosed with PCa (Group I) and 129 with no malignancy (Group II). Only a single patient had metastasis. On evaluating the area under the receiver operating characteristic curve of all study parameters, ΔNLR was the most accurate marker, followed by PSAD and then NLR measured at the last biopsy. Conclusions: ΔNLR was the most accurate marker to improve the total predictive value in repeat prostate biopsy for diagnosing PCa.

show abstract

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer

Cited by 40 publications

References 30 publications

Neutrophils in cancer

Neutrophils in cancer

Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis

Contact Info

Product

Resources

About